Galderma is the operating company of Nestlé Skin Health, a global leader focused on enhancing the quality of life by delivering science-based solutions for the health of skin, hair and nails. Five state-of-the-art R&D centers and six manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy.
For more information, please visit Galderma's website: http://www.galderma.com
References:
1) Shanler S, Ondo A. Successful treatment of the erythema and flushing of
rosacea using a topically applied selective a1 adrenergic receptor agonist,
oxymetazoline [abstract taken from J Am Acad Dermatol. 2008;58(2):AB9]. Presented at:
American Academy of Dermatology 66th Annual Meeting; February 1-5, 2008; San Antonio,
TX.
2) National Rosacea Society: All About Rosacea. Available at:
http://www.rosacea.org/patients/allabout... [Last accessed March 2015]
3) Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea:
report of the National Rosacea Society Expert Committee on the Classification and
Staging of Rosacea. J Am Acad Dermatol. 2004;50:907-912
For all media enquiries, please contact:
Media
Galderma
Sébastien Cros, +33-1-58-86-45-92
media@galderma.com
Photo:
http://photos.prnewswire.com/prnh/20150331/736613-a
http://photos.prnewswire.com/prnh/20150331/736613-b
http://photos.prnewswire.com/prnh/20150331/736613-c
